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The TGF-β superfamily is the largest family of secreted proteins in
mammals, and members of the TGF-β family are involved in most
developmental and physiological processes. Growth differentiation
factor 9 (GDF9) and bone morphogenetic protein 15 (BMP15), oo-
cyte-secreted paralogs of the TGF-β superfamily, have been shown
genetically to control ovarianphysiology.Althoughprevious studies
found that GDF9 and BMP15 homodimers can modulate ovarian
pathways in vitro, the functional species-speciﬁc signiﬁcance of
GDF9:BMP15 heterodimers remained unresolved. Therefore, we
engineered and produced puriﬁed recombinant mouse and human
GDF9 and BMP15 homodimers and GDF9:BMP15 heterodimers to
compare their molecular characteristics and physiological functions.
In mouse granulosa cell and cumulus cell expansion assays, mouse
GDF9 and human BMP15 homodimers can up-regulate cumulus ex-
pansion-related genes (Ptx3,Has2, and Ptgs2) and promote cumulus
expansion in vitro, whereas mouse BMP15 and human GDF9 homo-
dimers are essentially inactive. However, we discovered that mouse
GDF9:BMP15 heterodimer is ∼10- to 30-fold more biopotent than
mouse GDF9 homodimer, and human GDF9:BMP15 heterodimer is
∼1,000- to 3,000-fold more bioactive than human BMP15 homo-
dimer. We also demonstrate that the heterodimers require the ki-
nase activities of ALK4/5/7 and BMPR2 to activate SMAD2/3 but
unexpectedly need ALK6 as a coreceptor in the signaling complex
in granulosa cells. Our ﬁndings that GDF9:BMP15 heterodimers are
the most bioactive ligands in mice and humans compared with
homodimers explain many puzzling genetic and physiological data
generated during the last two decades and have important implica-
tions for improving female fertility in mammals.
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Ligands of the TGF-β superfamily, the largest family of secretedproteins in mammals, are synthesized as dimers and bind
transmembrane type 1 and type 2 serine-threonine kinase receptors
to activate downstream signaling cascades (e.g., the SMADs) in
many developmental, physiological, and pathophysiological pro-
cesses (1, 2). Growth differentiation factor 9 (GDF9) and bone
morphogenic protein 15 (BMP15) are key oocyte-secretedmembers
of the TGF-β superfamily and can regulate female fertility in several
mammals (2, 3). Although GDF9 and BMP15 are closely related
paralogs, they have been shown in vitro to signal through divergent
SMAD2/3 and SMAD1/5/8 pathways, respectively (4–6).
By studying gene knockouts and mutant models, putative roles
of GDF9 and BMP15 in female reproduction have been described
in mice, sheep, and humans. Our group previously discovered
that Gdf9-null female mice are sterile (7), and Gdf9+/−Bmp15−/−
double-mutant mice had more severe fertility defects than sub-
fertile Bmp15−/− mice (8, 9). BMP15 or GDF9 heterozygous mu-
tant sheep have increased litter size, whereas homozygousmutants
are sterile and phenocopy Gdf9−/− mice (10, 11). In humans,
mutations in GDF9 and BMP15 have been associated with pre-
mature ovarian failure and dizygotic twinning (12–14). These data
suggest synergistic functions of the two gene products andpotential
species-speciﬁc differences in the bioactivity of these proteins.
Although an in vitro study has detected the GDF9:BMP15 heter-
odimer by immunoprecipitation (15), and cooperative effects of
the two homodimers were studied by other groups (16–18), the
functions of GDF9:BMP15 heterodimers in any species remain
largely unknown.
In the present study, we demonstrate that GDF9:BMP15 heter-
odimers are the most bioactive ligands in the regulation of cumulus
expansion genes. These heterodimers signal through a unique BMP
receptor type 2 (BMPR2)-ALK4/5/7-ALK6 receptor complex to
induce the phosphorylation of SMAD2/3 in human and mouse
granulosa cells. Our ﬁndings open up prospects for the un-
derstanding of the synergistic roles ofGDF9 andBMP15 proteins in
ovarian functions and have important implications for improving
female reproductive productivity in mammals.
Results
Puriﬁcation of Human and Mouse GDF9:BMP15 Heterodimers and
Initial Testing of Their Activities. To reveal possible activities of
GDF9:BMP15 heterodimers in mammals, we engineered the
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Although genetic studies have uncovered critical functions of
GDF9 and BMP15 in female reproduction, many genetic and
physiologic data for these ligands remain perplexing. Here we
establish that mouse and human GDF9:BMP15 heterodimers are
the most biopotent regulators of ovarian granulosa cell func-
tions. Moreover, GDF9:BMP15 heterodimers require a unique
signaling complex that includes the type 2 receptor BMPR2, an
ALK4/5/7 type 1 kinase receptor, and an ALK6 type 1 co-re-
ceptor. GDF9:BMP15 binding to this complex stimulates phos-
phorylation of SMAD2/3. Our ﬁndings explain intraspecies and
interspecies functions of these oocyte-synthesized proteins and
have key implications for the regulation of female fertility.
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human (h) and mouse (m) GDF9 and BMP15 cDNAs to encode
subunit-speciﬁc tags (MYC or FLAG) at the N termini of the
proteins (Fig. S1A). The MYC and FLAG tags were critical for
puriﬁcation and accurate quantiﬁcation of the proteins. As in our
previous study (6), optimized proteolytic cleavage sites for the
mouse and human GDF9 and BMP15 precursors were inserted
before the epitope tags to facilitate production of the mature
proteins. We puriﬁed either homodimers (when the subunits
were expressed individually in HEK-293T cells) or heterodimers
(when both subunits were produced simultaneously in the same
cell) (Fig. 1A). Western blot analysis was used to detect BMP15
by anti-FLAG and GDF9 by anti-MYC (or anti-GDF9) when
both subunits were produced together (Fig. 1B and Fig. S1B).
Immunoprecipitation using anti-FLAG agarose yielded a mix-
ture of BMP15 homodimers (∼75%) and GDF9:BMP15 heter-
odimers (∼25%) because of the presence of the FLAG tag in
both dimers.
In response to the ovulatory luteinizing hormone surge, cumulus
cells become expanded and produce a complex extracellular matrix
(ECM), which is essential for ovulation, fertilization, and sub-
sequent embryonic development. This highly coordinated process
is known as “cumulus expansion” and requires oocyte-derived
paracrine factors (19, 20). Several genes expressed in granulosa
cells, including hyaluronan synthase 2 (Has2) (21, 22), pentraxin 3
(Ptx3) (23), and prostaglandin synthase 2 (Ptgs2) (24, 25), have been
shown to function in cumulus expansion. To determine whether the
mouse and human homodimers and heterodimers were bioactive,
we ﬁrst tested each ligand for its ability to induce Ptx3, Has2, and
Ptgs2 mRNAs in established mouse granulosa cell assays. The
hBMP15homodimer slightly stimulates cumulus expansion-related
gene expression at a high concentration (100 ng/mL), but the same
concentration of hGDF9 homodimer shows no activity compared
with the control (not treatedwith ligand) (Fig. 1C–E). Surprisingly,
hGDF9:BMP15 induces Ptx3, Has2, and Ptgs2 mRNA expression
to a greater extent at a 30-fold lower (3 ng/mL) concentration (Fig.
1 C–E). In addition to the untreated control, we set up another
control in which we treated mouse granulosa cells with a combi-
nation of hBMP15 and hGDF9 homodimers. The combination of
hBMP15 and hGDF9 homodimers at high concentrations did not
alter the induction of Ptx3,Has2, or Ptgs2 compared with hBMP15
alone (Fig. 1 C–E). We also performed similar experiments for
mouse homodimers and heterodimers (Fig. 1 F–H). In contrast to
human ligands,mGDF9 is a potent regulator of cumulus expansion
genes, but mBMP15 is inactive at the same concentration (100 ng/
mL). mGDF9:BMP15 heterodimer at a lower concentration (16
ng/mL) and a mixture mGDF9 and mBMP15 homodimers have
activity similar to that of mGDF9, although the inductions of Ptx3,
Has2, and Ptgs2 appeared to have reached maximum saturation
with the concentrations of mGDF9 and mGDF9:BMP15 ligands
used in this initial study.
h/mGDF9:BMP15 Heterodimers Are More Potent than Homodimers.
To quantify the heterodimer activities, we performed dose–re-
sponse experiments with human and mouse heterodimers in the
mouse granulosa cell assays (Fig. 2). Strikingly, 0.03 ng/mLhGDF9:
BMP15 has activity comparable to that of 100 ng/mL hBMP15
homodimer in up-regulating the three cumulus expansion-related
transcripts, indicating∼3,000-fold increased activity of the hGDF9:
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Fig. 1. Puriﬁcation of h/mGDF9:BMP15 and initial testing of their activities in mouse granulosa cell assay. (A) A plasmid containing MYC-tagged GDF9 and
FLAG-tagged BMP15 was transfected into HEK-293T cells to yield GDF9 (green), BMP15 (blue), and GDF9:BMP15 (bicolor). Use of anti-FLAG agarose allowed
immunoprecipitation of BMP15 and GDF9:BMP15. (B) After immunoprecipitation, h/mBMP15 was detected by anti-FLAG, and h/mGDF9 was detected by anti-
MYC. (C–H) Mouse granulosa cells were treated with no ligand (white), 100 ng/mL h/mBMP15 (h/mB15; blue), 100 ng/mL h/mGDF9 (h/mG9; green), 3 ng/mL
hGDF9:BMP15 or 16 ng/mL mGDF9:BMP15 (h/mG9:B15; orange), and a mix of 100 ng/mL homodimers (h/mB15+h/mG9; yellow) for 5 h. Total RNA was
extracted, and downstream ECM genes Ptx3 (C and F), Has2 (D and G), and Ptgs2 (E and H) were quantiﬁed by qPCR and are shown relative to the control (no
ligand) sample. Data in C–H represent the mean ± SEM (n = 3). *P < 0.05; **P < 0.01; ***P < 0.001 compared with controls not treated with ligand. (C–E)
Induction of Ptx3, Has2, or Ptgs2 with hBMP15 versus combination treatment was not statistically signiﬁcant. (F–H) Induction of Ptx3, Has2, or Ptgs2 with
mGDF9 versus combination treatment was not statistically signiﬁcant.
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BMP15 heterodimer comparedwith the hBMP15 homodimer (Fig.
2 A–C). In a parallel experiment for mouse ligands, mGDF9:
BMP15 is ∼10- to 30-fold more biopotent than mGDF9 homo-
dimer (Fig. 2 D–F).
Although these results show that GDF9:BMP15 heterodimers
are more potent than their homodimers in up-regulating cumu-
lus expansion-related transcripts, we investigated whether het-
erodimers are sufﬁcient to promote the full process of cumulus
expansion in vitro using previously described methods (26). In
the presence of epidermal growth factor (EGF), cumulus expansion
was induced when mouse oocytectomized (OOX) cumulus cell
complexes (i.e., with the resident oocyte microsurgically removed)
were treated with one of the four homodimers or with either het-
erodimer using serial dilutions (Fig. 3 A–E). Results of the OOX
complex expansion assay matched the results of the previous mouse
granulosa cell assay: hGDF9:BMP15 shows about 1,000-fold in-
creased activity comparedwith hBMP15, whereasmGDF9:BMP15
shows more than 10-fold enhanced biopotency compared with
mGDF9 (Fig. 3 F–G).
Identiﬁcation of the h/mGDF9:BMP15 Heterodimer SMAD Signaling
Pathway and Type 1 Receptor in Mouse Granulosa Cells. Although
GDF9 and BMP15 are closely related paralogs in the TGF-β su-
perfamily, the “active” species-speciﬁc homodimers signal via dif-
ferent SMAD pathways: SMAD2/3 for mGDF9 and SMAD1/5 for
hBMP15 (4–6). To deﬁne the downstream signaling cascades of the
heterodimers inmouse granulosa cells, we next examined SMAD1/
5/8 and SMAD2/3 phosphorylation levels 1 h after treatment with
hBMP15, mGDF9, or GDF9:BMP15 heterodimers (Fig. 4A).
Compared with the hBMP15 homodimer, the GDF9:BMP15 het-
erodimers and the mGDF9 homodimer showed minimal SMAD1/
5/8 phosphorylation. In contrast, mGDF9:BMP15 and hGDF9:
BMP15 dramatically stimulated SMAD2/3 phosphorylation, in-
dicating that SMAD2/3 is the major signaling pathway for GDF9:
BMP15 heterodimers. These ﬁndings corroborate the importance
of the SMAD2/3 pathways in cumulus cell physiology identiﬁed
genetically in our laboratory: SMAD2/3 double-knockout mice
have severely impaired fertility secondary to defects in cumulus
expansion (27), whereas SMAD1/5/8 triple knockouts display mi-
nor defects in fertility (28).
A previous in vitro study detected the interaction between
BMP15 and the BMP type 1 receptor, ALK6, by coimmunopreci-
pitation (5). Alk6-knockout female mice are sterile because of im-
paired cumulus expansion (29), suggesting that mGDF9:BMP15
may signal through ALK6 to promote cumulus cell expansion. To
test if ALK6 is involved in the heterodimer receptor complex, we
examined SMAD1/5/8 and SMAD2/3 phosphorylation in Alk6−/−
mouse granulosa cells after treatment with our ligands (Fig. 4B).
Because BMP15 is thought to signal through ALK6, phosphoryla-
tion of SMAD1/5/8 was reduced in Alk6−/− granulosa cells com-
pared with wild-type cells. Furthermore, ALK6 does not appear to
play a signiﬁcant role in GDF9 signaling, because SMAD2/3 sig-
naling was unchanged in theAlk6−/− granulosa cells. As anticipated,
h/mGDF9:BMP15 heterodimers were unable to phosphorylate
SMAD1/5/8 inAlk6−/− granulosa cells, but, unexpectedly, SMAD2/3
phosphorylation was abolished. These data indicate that ALK6 is
an important type 1 receptor for the heterodimers and is essen-
tial in the receptor complex for triggering downstream SMAD2/3
phosphorylation.
To investigate further other type 1 receptor-signaling pathways
for the heterodimers, inhibitors speciﬁc to particular type 1 re-
ceptor subgroups were coincubated with our ligands in the mouse
granulosa cell assay (Fig. 4 C–H). LDN-193189 (a dorsomorphin
derivative) is an inhibitor of ALK2/3/6 (30, 31), and SB-505124 is
an inhibitor of ALK4/5/7 (32). Both of these inhibitors function
primarily by preventing receptor-regulated SMAD phosphoryla-
tion. LDN-193189 signiﬁcantly decreased hBMP15 activity but
showed only a subtle effect on heterodimer action in one of our
quantitative PCR (qPCR) assays (Fig. 4C–E). This result indicates
that activation of SMAD2/3 by the GDF9:BMP15 heterodimer
does not require the kinase activity of ALK6 and also is consistent
with the lack of signiﬁcant SMAD1/5/8 phosphorylation after
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Fig. 2. h/mGDF9:BMP15 dose-dependent effects in downstream ECM gene regulation. Mouse granulosa cells were treated with serial dilutions of hGDF9:
BMP15 (0.01, 0.03, 0.1, 0.3, 1.0, and 3.0 ng/mL) or mGDF9:BMP15 (0.1, 0.3, 1.0, and 3.0 ng/mL). hBMP15 (100 ng/mL) or mGDF9 (10 ng/mL) was used as a positive
control. Gene expression of Ptx3 (A and D), Has2 (B and E), and Ptgs2 (C and F) was measured to quantify ligand activities. Data represent the mean ± SEM (n =
3). *P < 0.05; **P < 0.01; ***P < 0.001 compared with controls not treated with ligand.
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treatment with the heterodimers (Fig. 4A). In contrast, SB-505124
abolished heterodimer activities, similar to its actions in inhibiting
mGDF9 (Fig. 4 F–H). Thus, ALK4/5/7 is the signaling type 1 re-
ceptor for GDF9:BMP15 heterodimers and, in combination with
a nonsignaling ALK6 receptor, regulates downstreamECMgenes.
Identiﬁcation of the h/mGDF9:BMP15 Heterodimer Type 2 Receptor in
Mouse Granulosa Cells. In vitro, BMPR2 is a type 2 receptor for
both GDF9 and BMP15 (5, 33). To identify the GDF9:BMP15
heterodimer type 2 receptor, we compared SMAD2/3 phosphor-
ylation levels among treatments with different type 2 receptor
extracellular domains (ECDs): BMPR2, ACVR2A, ACVR2B,
and TGFBR2 (Fig. 5A and Fig. S2). Only the BMPR2 ECD
decreased the activities of mGDF9 and h/mGDF9:BMP15 in
SMAD2/3 phosphorylation assays.
To test further the importance of BMPR2 as a heterodimer type
2 receptor in the regulation of cumulus expansion genes, we de-
termined if the BMPR2 ECD could decrease activities of GDF9:
BMP15 heterodimers in the mouse granulosa cell assay.We found
that BMPR2 ECD attenuated the up-regulation of ECM gene
expression by h/mGDF9:BMP15 heterodimers as well as by
hBMP15 and mGDF9 (Fig. 5 B–G).
Conﬁrmation of the SMAD Signaling Pathway by the h/mGDF9:BMP15
Heterodimer in Human Granulosa Cells. To validate our conclusions
in human granulosa cells, we tested GDF9:BMP15 heterodimer
activities in COV434 cells, an immortalized human granulosa cell
line. Similar to the results inmouse granulosa cells, active hBMP15
and mGDF9 homodimers signal via SMAD1/5/8 and SMAD2/3,
respectively (Fig. 6A). The h/mGDF9:BMP15 heterodimers use
SMAD2/3 as the major signaling pathway (Fig. 6A). Furthermore,
assay results in COV434 cells conﬁrmed that the high activity of
hGDF9:BMP15 is not the result of a synergistic effect of hGDF9
and hBMP15 homodimers (Fig. 6B).
In dose–response experiments, h/mGDF9:BMP15 heterodimers
show dramatically higher activities in SMAD2/3 phosphorylation
than their corresponding homodimers (Fig. 6 C and D). We ob-
served SMAD2/3 phosphorylation at the lowest tested dose (0.1 ng/
mL) of the hGDF9:BMP15 heterodimer, but there was no appar-
ent SMAD2/3 phosphorylation by the hGDF9 and hBMP15
homodimers when tested at a dose of 100 ng/mL (Fig. 6C). This
result conﬁrms the >1,000-fold higher activity of hGDF9:BMP15
compared with hBMP15 that we observed in our mouse granulosa
cell assays. When we tested mGDF9 homodimer in the COV434
cells, we observed low phosphorylation of SMAD2/3 at 10 ng/mL of
GDF9, approximating the SMAD2/3 phosphorylation by mGDF9:
BMP15 heterodimer (0.1–0.3 ng/mL) (Fig. 6D). This result also
conﬁrms the∼30-fold higher activity ofmGDF9:BMP15 compared
with GDF9 that we observed in mouse granulosa cell assays.
Last, we examined the effects of the type 1 inhibitors and type
2 ECDs on the ligand-signaling pathways in COV434 cells. The
heterodimer activities in SMAD2/3 phosphorylation assays were
abolished speciﬁcally by SB-505124 but not by LDN-193189 (Fig.
6 E and F), conﬁrming that ALK4/5/7 is the type 1 receptor ki-
nase that phosphorylates SMAD2/3 in human as well as mouse.
To evaluate the GDF9:BMP15 heterodimer type 2 receptor in
COV434 cells, we compared SMAD2/3 phosphorylation levels
among treatments with four different type 2 receptor ECDs and
found that only BMPR2 ECD decreased activities of mGDF9
and hGDF9:BMP15 in SMAD2/3 phosphorylation (Fig. S3).
Discussion
Previous studies have identiﬁed a number of heterodimeric TGF-β
ligands that have novel functions or enhanced potency compared
with the homodimers. For example, inhibins (α:βA and α:βB) an-
tagonize activins (βA:βA, βB:βB, and βA:βB) through their binding
to speciﬁc and unique receptors (1, 34), and BMP2:BMP7 hetero-
dimers show a speciﬁc activity about 20-fold higher than their
homodimers in vitro (35). In our studies presented here, we show
even more potent bioactivity of recombinant GDF9:BMP15 het-
erodimers. Based on the results in our paper and the genetic and
physiologicﬁndings inmice, rats, sheep, and human,wenowpresent
models for the respective activity of homodimers and heterodimers
in these species (Fig. 7). In humans, the recombinantGDF9:BMP15
heterodimer was the most bioactive ligand in cumulus expansion in
vitro, having more than 1,000-fold greater activity than BMP15
homodimer, whereas GDF9 homodimer was essentially inactive
(Fig. 7A). Alternatively, using recombinant mouse dimers, we
established that theGDF9:BMP15 heterodimer is∼10- to 30-fold
more biopotent than the mGDF9 homodimer, whereas the
mBMP15 homodimer is inactive (Fig. 7B). These ﬁndings are
consistent with the genetic ﬁndings in several species. Gdf9-
knockout mice are sterile (7) because they lack the ability to syn-
thesize two active dimers (GDF9:BMP15 and GDF9:GDF9). Al-
ternatively, Bmp15-knockout mice are subfertile because they fail
to synthesize the most active dimer (GDF9:BMP15) (8). These
genetic ﬁndings indicate that the continued synthesis of the less
active GDF9:GDF9 homodimer partially compensates for hetero-
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Fig. 3. h/mGDF9:BMP15 dose-dependent effects in OOX cumulus cell ex-
pansion. (A–E) Representative photographs of OOX cumulus cells treated
with no ligand (A), 30 ng/mL hBMP15 (B), 30 ng/mL mGDF9 (C), 0.3 ng/mL
hGDF9:BMP15 (D), or 0.3 ng/mL mGDF9:BMP15 (E) in the presence of EGF (10
ng/mL). (F–G) OOX cumulus cells were treated with 30 ng/mL homodimers
and a 1:10 serial dilution of hGDF9:BMP15 (0.0003, 0.003, 0.03, 0.3, and 3.0
ng/mL) or mGDF9:BMP15 (0.3 and 3.0 ng/mL) to test dose-dependent effects
in OOX cumulus cell expansion. Data in F and G represent the mean ± SEM
(n = 10). ***P < 0.001 compared with controls not treated with ligand.
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dimer absence and can cooperate with GDF9:BMP15 hetero-
dimers to regulate granulosa cell function exclusively through the
SMAD2/3 pathway (Fig. 7B). However, with a further reduction in
the production of theGDF9 subunit,Gdf9+/−Bmp15−/−mutantmice
show profound fertility defects, and when the mutations are present
on a 129 inbred genetic background, these mice are sterile (8).
During evolution,mutations that cause a gene product to become
inactive and unnecessary could result eventually in loss of a gene.
Thus, the lack of signiﬁcant activity of mouse BMP15 homodimers
or humanGDF9 homodimers in granulosa cell assays would suggest
that these ligand-encoding genes would disappear during evolution.
However, the continued presence of both a BMP15 gene and
a GDF9 gene in more than 30 evolutionarily diverse mammalian
species and other vertebrates sequenced to date suggests that het-
erodimers are the most active forms within many, if not all, of these
species. Unlike other TGF-β family members such as activin βA,
which is nearly 100% conserved in its mature amino acid sequence
in almost all mammals, our group previously showed that mouse
and human BMP15 mature domains share only 69.6% identity, but
mouse and human GDF9 mature domains have 89.6% amino acid
identity. Likewise, sheepBMP15 is divergent compared with mouse
and human BMP15 (78.9% identity with each), but the mature se-
quence of sheepGDF9 shows 87.4%and 92.6% identitywithmouse
and human GDF9, respectively. Coevolutionary divergence in the
GDF9 and BMP15 mature coding sequences may have allowed
GDF9:BMP15 heterodimers to form, be more active than homo-
dimers, and function as the essential oocyte-secretedTGF-β dimers,
especially in women and sheep, and likely in most other mammals.
Previous in vitro studies indicate that the human BMP15 homo-
dimer signals through a complex of BMPR2 (type 2) and ALK6
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Fig. 4. Identiﬁcation of the h/mGDF9:BMP15 SMAD-signaling pathway and type 1 receptors in mouse granulosa cells. (A) Wild-type granulosa cells were
treated with ligands (100 ng/mL hBMP15, 100 ng/mL mGDF9, 3 ng/mL hGDF9:BMP15, and 16 ng/mL mGDF9:BMP15) for 1 h. Anti–P-SMAD1/5/8 and anti–P-
SMAD2/3 were used to detect the two SMAD-signaling pathways. Actin was used as the internal control. (B) Alk6−/− granulosa cells were treated with the
same ligands to examine the phosphorylation of SMAD1/5/8 and SMAD2/3. Actin was used as the internal control. (C–H) The ALK2/3/6 inhibitor LDN-193189
(100 nM) or the ALK4/5/7 inhibitor SB-505124 (1 μM) was coincubated with the ligands to test if the induction of downstream ECM genes Ptx3 (C and F), Has2
(D and G), and Ptgs2 (E and H) was abolished compared with controls not treated with inhibitor. Data in C–H represent the mean ± SEM (n = 3). *P < 0.05;
**P < 0.01; ***P < 0.001.
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(type 1) (5, 36). Ligand binding to the complex causes BMPR2 to
phosphorylate ALK6, which subsequently phosphorylates SMAD1/
5/8 to regulate gene expression (Fig. 7A). Alternatively, mouse
GDF9 homodimers signal through a complex that includes BMPR2
and ALK4/5/7 (Fig. 7B). Ligand-induced dimerization of the type 2
and type 1 receptors results in ALK4/5/7 phosphorylation and sub-
sequent phosphorylation of SMAD2/3. Although rat GDF9
homodimers have been reported to signal through ALK5 in an in
vitro assay (4), our group discovered thatAlk5 conditional knockout
(cKO) mice have no defects in follicular development and cumulus
expansion, indicating that ALK5 is not the type 1 receptor through
which the GDF9 homodimer signals in the mouse ovary (37). Like
BMP15 and GDF9 homodimers, mouse and human GDF9:BMP15
heterodimers signal through BMPR2. Type 1 inhibitor studies in-
dicate that mouse and human GDF9:BMP15 heterodimers require
the kinase activity of ALK4/5/7 but do not require kinase signaling
from ALK2/3/6. Because GDF9:BMP15 heterodimers are the most
active ligands in our granulosa cell assays, and the Alk5 cKO mice
show normal cumulus expansion (37), unlike Gdf9+/−Bmp15−/−
double-mutant mice (8), we also can exclude ALK5 as the type 1
receptor for the GDF9:BMP15 heterodimer. Furthermore, ALK7
has relatively low expression in the ovary (38). Thus, ALK4 is the
most likely type 1 kinase receptor for GDF9:BMP15 heterodimers
to phosphorylate SMAD2/3, although this possibility must be tested
genetically.
Although the ALK2/3/6 kinase inhibitor LDN-193189 fails to
block signaling of mouse and human GDF9:BMP15, the hetero-
dimers fail to signal when ALK6-null granulosa cells are used in our
assays. Thus, when the heterodimer binds the complex, BMPR2
(type 2) phosphorylates ALK4 (type 1), and activated ALK4 phos-
phorylates SMAD2/3 (Fig. 7). Because ALK6 kinase activity is not
required for heterodimer signaling, ALK6 must function as a “co-
receptor” in the complex. Therefore, our studies reveal that GDF9:
BMP15 heterodimers signal through a BMPR2-ALK4/5/7-ALK6
complex. Like other TGF-β–signaling homodimers and hetero-
dimers, the GDF9:BMP15 heterodimeric ligands bind a complex of
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two type 2 receptors (in this case BMPR2) and two type 1 receptors
[in this case, ALK4 (likely) and ALK6]. Because ALK6 kinase ac-
tivity is not necessary, it is possible that BMPR2 fails to phosphor-
ylate ALK6, and therefore ALK6 remains in a nonphosphorylated
(inactive) state. As reviewed recently (39), heterodimeric members
of the BMP subfamily are more potent in vitro and in vivo because
(i) the heterodimers show higher-afﬁnity binding than homodimers
to type 1 and 2 receptors; (ii) the ligand:receptor complex is more
stable at the cell surface (i.e., is not degraded as quickly); (iii) the
heterodimers show lower binding to extracellular protein antago-
nists; and (iv) binding of the heterodimeric ligands results in
a unique conformation of the receptors including the type 1
receptors. This last point is likely true because we failed to observe
SMAD1/5/8 phosphorylation despite the inclusion ofALK6protein
in the complex. Because ALK6 has been shown to have higher af-
ﬁnity for ligands than ALK4, incorporating ALK6 into the receptor
complexmay provide amechanism for localizing theGDF9:BMP15
ligand to the cell surface and thereby stabilizing the signaling
complex. Because a variety of TGF-β dimers (i.e., activins, inhibins,
and BMPs) are expressed throughout ovarian folliculogenesis in all
mammals and use similar combinations of these signaling receptors
(1, 2), a signiﬁcant ligand–receptor competition exists in vivo.
Therefore, the heightened activity of the heterodimers and unique
combination of type 1 and type 2 receptors could result in increased
spatiotemporal signaling speciﬁcity of the oocyte-secreted hetero-
dimers in the ovaries of women and ewes.
Relative to the activity of GDF9:BMP15 heterodimers, why do
mice (and rat) GDF9 homodimers have signiﬁcant activity (22,
40) compared with human (and sheep) homodimers? In mice,
Gdf9 and Bmp15 share similar expression patterns: They have
low levels of expression in oocytes of primary follicles and in-
crease in oocytes of growing follicles through ovulation (22, 41).
Similarly, in the rat GDF9 and BMP15 are expressed in oocytes
beginning at the early primary follicle (40, 42). However, al-
though Gdf9-null mice are infertile because folliculogenesis is
blocked at the primary follicle stage (7), Alk6-null females are
infertile because of defects in cumulus expansion (29). Further-
more, Alk6 is expressed in mouse and rat granulosa cells be-
ginning at the secondary (two-layer; type 4) follicle stage (29, 42).
These studies and our data suggest that only GDF9 homodimers
are required for signaling at the primary follicle stage in mice
and rat and indicate that in rodents GDF9:BMP15 heterodimers
play a major role in cumulus expansion and ovulation at the
preovulatory stage when ALK6 is present (Fig. 7B). In contrast,
ALK6 is expressed in sheep granulosa cells beginning at the pri-
mordial (type 2) follicle stage (17), andmutations inbothGDF9and
BMP15 cause a similar block at the primary follicle stage (10, 11).
Thus, in sheep, we predict that the activity of the homodimers is
somewhat irrelevant, because ALK6 is expressed and GDF9:
BMP15 heterodimers are expected to be potent, as in humans (Fig.
7A). Unfortunately, we have been unable to identify GDF9:BMP15
heterodimers from either mouse ovary or human follicular ﬂuid
because of the lack of high-afﬁnity antibodies to mouse BMP15 and
the low levels of these oocyte-secreted proteins (either homodimers
or heterodimers) in follicular ﬂuid.
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Fig. 6. Identiﬁcation of the h/mGDF9:BMP15 SMAD-signaling pathway and type 1 receptors in COV434 cells. (A) COV434 cells were treated with 100 ng/mL
hBMP15, 100 ng/mL mGDF9, and 3 ng/mL h/mGDF9:BMP15 for 1 h. Anti–P-SMAD1/5/8 and anti–P-SMAD2/3 were used to detect the two P-SMAD–signaling
pathways. Actin was used as the internal control. (B) COV434 cells were treated with 100 ng/mL hBMP15, 100 ng/mL hGDF9, and 3 ng/mL hGDF9:BMP15 and
a mix of their homodimers (100 ng/mL) for 1 h. Anti–P-SMAD2/3 was used to deﬁne ligand activities. Actin was used as the internal control. (C and D) (Left)
COV434 cells were treated with serial dilutions of hBMP15 or mGDF9 (1.0, 10, or 100 ng/mL) or h/mGDF9:BMP15 (0.1, 0.3, 1.0, or 3.0 ng/mL) to test the dose-
dependent effect on SMAD2/3 phosphorylation. Actin was used as the internal control. (Right) Western blots of three independent experiments were
quantiﬁed, and the data are shown as the mean ± SEM (n = 10). ***P < 0.001 compared with controls not treated with ligand. (E and F) The ALK2/3/6 inhibitor
LDN-193189 (100 nM) or the ALK4/5/7 inhibitor SB-505124 (1 μM) was coincubated with the ligands to test if the induction of SMAD phosphorylation was
abolished compared with controls with no inhibitor treatment. Actin was used as the internal control.
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Our data also have important implications for human oocyte
in vitro maturation (IVM), an infertility treatment modiﬁcation
of traditional in vitro fertilization protocols (43). The objectives
of IVM in human assisted reproductive technology (ART) are to
avoid side effects of exogenous gonadotropins, to increase fetal
viability, and to reduce the cost of infertility treatments. High
expression of cumulus expansion-regulated genes (e.g., PTGS2,
HAS2) is correlated with high-quality embryos in the ART clinic
(44–46), and we have shown that GDF9:BMP15 heterodimers
are the most bioactive ligands to up-regulate these ECM genes in
vitro. However, because oocyte developmental competence is
enhanced by oocyte-derived paracrine factors during IVM (47),
GDF9:BMP15 heterodimers are potential ligands for promoting
oocyte developmental competence in vitro during IVM and
provide new opportunities for treatment of human infertility.
Materials and Methods
Construction of Expression Plasmids. Plasmids containing the native h/mGDF9
and h/mBMP15 cDNAwere used as templates, and overlap extension PCR was
performed to engineer optimized cleavage sites and FLAG- or MYC-tag
sequences before the ligand mature domains as well as to fuse the pre-
propeptide and modiﬁed mature domains (6). To enhance the expression of
mGDF9/BMP15 in HEK-293T cells, the mature mouse prepro domain was
replaced by the human prepro domain (Fig. S1A). For homodimer expression
plasmids, FLAG-tagged h/mGDF9 or h/mBMP15 sequences were cloned into
pEFIRES-P. For heterodimer expression plasmids, both MYC-tagged h/mGDF9
and FLAG-tagged h/mBMP15 were cloned into pCEBud4.1 (Invitrogen). MYC-
h/mGDF9 is under the control of the EF-1α promoter, whereas FLAG-h/
mBMP15 is under the control of the CMV promoter in pCEBud4.1. The cDNAs
encoding the engineered precursor sequences in the expression plasmids
were conﬁrmed by DNA sequencing.
Transfection and Selection of Stable Cell Clones. HEK-293T cells were obtained
from the tissue culture core at Baylor College of Medicine and cultured in
DMEM containing 10% (vol/vol) FBS and 100 μg/mL penicillin–streptomycin.
All plasmids were transfected into HEK-293T cells using FuGENE6 (Roche)
transfection reagent according to the manufacturer’s instructions. Two days
after transfection, cells containing the homodimer expression plasmids
(pEFIRES-P) were selected with 5 μg/mL of puromycin (Invitrogen), and cells
containing the heterodimer expression plasmids (pCEBud4.1) were selected
under 500 μg/mL of Zeocin (Invitrogen). Puromycin/Zeocin-resistant cell
colonies were selected 2 wk after transfection, and protein expression was
conﬁrmed by Western blot. HEK-293 hBMP15 stable cell lines were gener-
ated as described in our previous study (6).
Protein Puriﬁcation, Quantiﬁcation, and Immunoprecipitation. When stable
cells reached conﬂuency, DMEM containing 2% (vol/vol) FBS and 100 μg/mL
penicillin–streptomycin was used for the production of recombinant pro-
teins. Roller-bottle cultures were harvested 5 d after seeding, and dishes
were harvested 3 d after seeding. Puriﬁcation of FLAG-tagged homodimers
was conducted using anti-FLAG M2 afﬁnity gel (Sigma-Aldrich) according to
the manufacturer’s protocol. The FLAG-tagged homodimers were eluted
with 3× FLAG elution buffer (25 μg/μL in Tris-buffered saline, pH8.0), and 1
mg/mL BSA was added to the proteins before storage at −80 °C. The puriﬁed
FLAG-tagged ligands were quantiﬁed by Western blot using FLAG-bacterial
alkaline phosphatase standards and mouse anti-FLAG M2 antibody (Sigma-
Aldrich) (Fig. S1B, Left). MYC-GDF9:FLAG-BMP15 heterodimers were immu-
noprecipitated by the same method as above. The puriﬁed MYC-m/hGDF9
was quantiﬁed using FLAG-mGDF9 standards with a GDF9 monoclonal anti-
body as described in our previous study (22) (Fig. S1B, Right).
Mouse Granulosa Cell Isolation. Mice used in this study were maintained on
a mixed C57BL/6/129S6/SvEv genetic background and handled according to
the National Institutes of Health Guide for the Care and Use of Laboratory
Animals (48). Female mice 21–24 d of age were injected with 5 IU pregnant
mare’s serum gonadotropin, and ovaries were harvested 44–46 h after in-
jection. Mouse granulosa cells were released by puncturing large antral
follicles. The collection medium was DMEM/F12 containing 0.3% BSA, 100
μg/mL penicillin–streptomycin, and 10 mM Hepes. To remove oocytes, the
cell suspension was ﬁltered through a 40-μm nylon cell strainer and washed
twice with collection medium.
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Mouse and Human Granulosa Cell Assays. Mouse granulosa cells and COV434
cells were maintained in DMEM/F12 containing insulin-transferrin-sodium
selenite supplement (Sigma-Aldrich), 0.5% heat-inactivated FBS, and 100 μg/
mL penicillin–streptomycin. In the gene-induction assays, mouse granulosa
cells were treated with ligands for 5 h, and total RNA was extracted. Real-
time PCR was conducted to test the fold changes of Ptx3, Has2, and Ptgs2.
For SMAD activation analysis, mouse granulosa cells and COV434 cells were
treated with ligands for 1 h and lysed with RIPA buffer in the presence of
proteinase and phosphatase inhibitors (Roche). SMAD phosphorylation was
detected by Western blot with anti–P-SMAD1/5/8 or anti–P-SMAD2/3 (Cell
Signaling). Actin was used as the internal control detected by monoclonal
anti-actin (Sigma-Aldrich).
Mouse Cumulus Expansion Assay. In vitro mouse cumulus expansion assays
were performed as described previously (49). Brieﬂy, oocytes were removed
from oocyte-cumulus cell complexes using a microsurgical apparatus. The
resulting OOX complexes consisted of the spherical zona pellucida sur-
rounded by the cumulus cell mass without the oocyte. The culture medium
used in the assay was Eagle’s minimal essential medium (MEM) alpha me-
dium containing 5% (vol/vol) FBS and 10 mM milrinone (Sigma-Aldrich). Ten
OOX cumulus cells were treated with ligands in the presence of 10 ng/mL
EGF. After 15 h incubation, the cumulus expansion index was scored based
on the degree of OOX cumulus cell expansion using a scale from 0 (no ex-
pansion) to 4 (complete expansion) (49).
Receptor Selectivity Assay. Mouse granulosa cells or COV434 cells were
treated with ligand and coincubated with/without 100 nM LDN-193189,
1 μM SB-505124, or 1 μg BMPR2, ACVR2A, ACVR2B, or TGFBR2 ECD with an
Ig Fc tag (R&D). For BMPR2* (made in the laboratory of T.B.T), the ECD
of hBMPR2 (amino acids 27-150) was cloned into the pFUSE-Fc vector
(Invivogen). Recombinant hBMPR2-Fc fusion protein was generated by
transient expression in HEK-293 Freestyle cells and puriﬁed by afﬁnity
chromatography using protein G afﬁnity resin.
Real-Time PCR.Gene expression was analyzed by real-time PCR using the 7500
Fast Real-time System (Applied Biosystems). Taqman gene-expression probes
(Ptx3Mm00477267_g1, Has2Mm00515089_m1, and Ptgs2mM00478374_m1)
were used to test the fold changes of the three transcripts. All real-time PCR
analyses were performed in duplicate, and the results were reported from at
least three independent experiments. The relative fold change of transcript
was calculated by the 2−ΔΔCT method as described previously (50) and was
normalized to Gapdh as an endogenous reference.
Statistical Analysis. All experiments presented in this study were repeated at
least three times independently. Differences among groups were analyzed
for statistical signiﬁcance by using one-way ANOVA followed by Tukey’s
multiple comparison test. Comparison of means between two groups was
made by Student t test. The data represent the mean ± SEM, and P < 0.05
was considered to be statistically signiﬁcant.
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